To help gauge progress towards national goals (see sidebar) and direct HIV prevention resources most effectively, CDC tracks the "HIV care continuum. " The continuum is the series of steps from the time a person receives a diagnosis of HIV through the successful treatment of their infection with HIV medications. This fact sheet explains the various approaches and data used to develop the HIV care continuum, how it is used to improve outcomes for people living with HIV in the United States and how it helps guide the nation's response to HIV.
National HIV Prevention Objectives on HIV Diagnosis and Care
At the national level, several specific goals related to early HIV diagnosis and effective care include:
Increasing the number of HIVpositive individuals aware of their status to 90%
Increasing the proportion of persons with newly diagnosed HIV who are linked to care within one month to 85%
Increasing the proportion of HIVdiagnosed individuals whose virus is effectively suppressed to 80%, with an emphasis on youth and persons who inject drugs
What is the HIV Care Continuum?
The ultimate goal of HIV treatment is to achieve viral suppression, meaning the amount of HIV in the body is very low or undetectable. This is important for people with HIV to stay healthy, live longer and reduce their chances of passing HIV to others.
The HIV care continuum consists of several steps required to achieve viral suppression. Specifically, CDC tracks:
Diagnosed
Linked to care*, meaning they visited a health care provider within: -1 month (30 days) after learning they were HIV positive Received or were retained in care**, meaning they received medical care for HIV infection Viral suppression, meaning that their HIV "viral load" -the amount of HIV in the blood -was at a very low level * Linked to care is calculated differently from other steps in the continuum, and cannot be directly compared to other steps. See Table 1 This approach allows us to monitor elements of the care continuum by measuring the care outcomes among all Americans living with HIV. It can also monitor outcomes for broad populations, such as African Americans or men who have sex with men (MSM). However, because of certain statistical limitations, this approach does not allow more segmented analyses within those populations, such as young black MSM. See Figure 1 for the 2014 Prevalence-Based HIV Care Continuum.
Linked to Care:
In 2015, 75% of persons receiving a diagnosis of HIV were linked to care within 1 month Defined as linkage to care within 1 month of HIV diagnosis
Denominator is persons receiving a diagnosis of HIV in a measurement year; numerator is the number of persons who were linked to care within 1 month
Because it has a different denominator, it cannot be directly compared to other steps See Table 1 on page 4 for additional details 
How CDC Develops the Continuum
The data for both the prevalence-and diagnosis-based continua of care approaches come from:
The National HIV Surveillance System (NHSS) provides a range of information on people who have diagnosed HIV or have died with HIV from every U.S. state and territory and the District of Columbia, including race/ethnicity, route of transmission and age. The data are reported to CDC by state and local health departments. This is the source of data for both the prevalence and diagnosis denominators. Data from the states and D.C. that have complete laboratory reporting are used to calculate some measures of the continuum.
Not all steps in the care continuum are necessarily dependent on the previous step. For additional details on the two continuum approaches, see Table 1 below. Some of these indicators are also used to monitor progress toward national goals. For more information on national indicators, please see https://www.cdc.gov/hiv/pdf/library/factsheets/ cdc-hiv-national-hiv-care-outcomes.pdf.
What is CDC Doing to Improve the Outcomes at Every Stage of the HIV Care Continuum?
CDC is undertaking many initiatives including:
Directly funding health departments and community-based organizations (CBOs) -to increase HIV testing, improve linkages to care and support improvement of viral suppression for persons living with HIV and improve linkages to PrEP and other prevention services for persons who are at risk for HIV.
Providing technical assistance -to help health departments and CBOs develop the tools and skills to successfully implement effective HIV prevention activities for people living with HIV in their communities.
Improving surveillance capability and technology -to assist states with improving completeness of laboratory data that are needed to assess many of the steps in the HIV care continuum and the selected national HIV care outcomes.
Researching new approaches -including studies of clinical, behavioral and structural interventions to help people with HIV stay in care and adhere to their medications.
Developing guidelines -for health care providers on HIV testing, care, treatment, and prevention.
Launching educational campaigns and a HIV Risk Reduction Tool -to help health care providers integrate simple prevention approaches into routine care for people living with HIV and to help all audiences understand risks for HIV.
Different Approaches for Different Needs
CDC's current approaches draw on the best data available.
It is important to know how the continuum will be used. Some uses of the prevalence-based continuum include:
Monitoring testing efforts in the U.S. and demonstrating the importance of diagnosing HIV infections to achieve viral suppression Ways of presenting the continuum will also continue to evolve over time, as better and more complete data become available. Measures the percentage of the total number of people living with HIV whose infection has been diagnosed.
The denominator for this continuum step is HIV prevalence, which is the total number of people living with HIV (includes both those with diagnosed infection and those with undiagnosed infection). HIV prevalence is estimated through statistical modeling using NHSS data from all U.S. states and the District of Columbia.
NHSS data from states and D.C. with complete reporting of CD4 and viral load test results are used to estimate "receipt of care" and "retained in care. "
Receipt of care is measured as the percentage of persons with diagnosed HIV who had at least 1 CD4+ or viral load test.
The denominator for the prevalence-based continuum is all persons living with HIV (HIV prevalence). The denominator for the diagnosis-based continuum is all persons living with diagnosed HIV (diagnosed prevalence*).
NHSS data from states and D.C. that have complete laboratory reporting are used to determine viral suppression.
Retained in care is measured as the percentage of persons with diagnosed HIV who had two or more viral load or CD4+ tests, performed at least three months apart.
NHSS data from states and D.C. with complete reporting of CD4 and viral load test results are used to determine "linked to care. "
Linked to care measures the percentage of people receiving a diagnosis of HIV in a given calendar year who had one or more documented viral load or CD4+ test within 30 days (1 month) of diagnosis.
Because this measure is limited to people with HIV diagnosed only in a single year, it cannot be directly compared to other steps in the continuum. This means that the denominator for linkage to care is different from the denominators used to calculate the other steps in the continuum. It is also important to note that an individual who enters care more than 30 days after diagnosis may still be included in subsequent steps of the continuum, but would not be counted as "linked to care. "
Continuum Step
* Diagnosed prevalence is defined as the number of persons diagnosed with HIV through the end of one year and are living through the end of the next year (e.g., diagnosed prevalence for 2014 is defined as persons receiving a diagnosis of HIV in 2013 and living through the end of 2014.)
